Published in Lancet on July 19, 1986
Cholera. Clin Microbiol Rev (1995) 12.33
Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev (1992) 5.15
Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Microbiol (2009) 2.79
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev (1992) 2.02
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci U S A (1989) 1.74
Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis (2011) 1.73
The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med (2015) 1.71
The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis (2011) 1.70
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun (1993) 1.52
Rotavirus diarrhea in Bangladeshi children: correlation of disease severity with serotypes. J Clin Microbiol (1992) 1.44
Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun (1989) 1.41
Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun (1992) 1.33
Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis (2011) 1.33
Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis (2012) 1.21
Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2011) 1.20
Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun (1987) 1.20
Rotavirus-associated diarrhea in rural Bangladesh: two-year study of incidence and serotype distribution. J Clin Microbiol (1991) 1.18
Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins. Infect Immun (1990) 1.18
Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Infect Immun (1991) 1.15
Causal inference for vaccine effects on infectiousness. Int J Biostat (2012) 1.15
Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau. PLoS Negl Trop Dis (2012) 1.14
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A (2010) 1.11
Natural cholera infection-derived immunity in an endemic setting. J Infect Dis (2011) 1.09
New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol (2011) 1.08
Enteric adenovirus infection among infants with diarrhea in rural Bangladesh. J Clin Microbiol (1993) 1.06
Oral immunization of rabbits with enterotoxigenic Escherichia coli protects against intraintestinal challenge. Infect Immun (1988) 1.02
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
Spatial clustering in the spatio-temporal dynamics of endemic cholera. BMC Infect Dis (2010) 1.01
Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLoS Negl Trop Dis (2014) 0.99
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ (1998) 0.99
Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect Immun (2010) 0.98
Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision. Infect Immun (2000) 0.98
Review of oral cholera vaccines: efficacy in young children. Infect Drug Resist (2011) 0.97
Spatial and environmental connectivity analysis in a cholera vaccine trial. Soc Sci Med (2009) 0.97
Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun (2009) 0.95
Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis (2012) 0.94
Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun (1989) 0.93
Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks. PLoS Negl Trop Dis (2013) 0.92
Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect Immun (1997) 0.90
A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia. Am J Trop Med Hyg (2015) 0.87
A cost effective and effective approach to the diagnosis and management of acute infectious diarrhea. Bull N Y Acad Med (1987) 0.87
Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens. Infect Immun (1989) 0.87
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum Vaccin Immunother (2015) 0.86
Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea. BMC Infect Dis (2009) 0.84
Cholera toxin B: one subunit with many pharmaceutical applications. Toxins (Basel) (2015) 0.83
Oral cholera vaccine development and use in Vietnam. PLoS Med (2014) 0.83
Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit. Infect Immun (1995) 0.83
The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine (Auckl) (2011) 0.82
Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum). Plant Cell Rep (2007) 0.81
Killed oral cholera vaccines: history, development and implementation challenges. Ther Adv Vaccines (2014) 0.81
Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Negl Trop Dis (2015) 0.79
Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea: a prospective cohort study. Hum Vaccin Immunother (2013) 0.79
Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin Vaccine Immunol (2014) 0.79
Immunization with cholera toxin B subunit induces high-level protection in the suckling mouse model of cholera. PLoS One (2013) 0.78
Removal of cholera toxin from aqueous solution by probiotic bacteria. Pharmaceuticals (Basel) (2012) 0.75
Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination. Infect Immun (1988) 0.75
The hows and whys of constructing a native recombinant cholera vaccine. Bioengineered (2013) 0.75
Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers. Infect Immun (1989) 0.75
Vaccines for cholera control: does herd immunity play a role. PLoS Med (2007) 0.75
Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit. Vaccine (2008) 0.75
Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2017) 0.75
Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun (1975) 13.58
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med (1976) 7.57
Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med (2001) 7.47
Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med (1976) 6.52
Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med (2000) 6.43
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med (1991) 6.07
Prostitution and risk of HIV: female prostitutes in London. BMJ (1993) 6.06
Typhoid fever in children aged less than 5 years. Lancet (1999) 6.00
The body-mass index of twins who have been reared apart. N Engl J Med (1990) 5.11
Special Escherichia coli serotypes among enterotoxigenic strains from diarrhoea in adults and children. Med Microbiol Immunol (1976) 4.95
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry (1984) 4.72
Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ (1991) 4.67
Reproductive-tract infections in women in low-income, low-prevalence situations: assessment of syndromic management in Matlab, Bangladesh. Lancet (1999) 4.67
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 4.62
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 4.56
Does rectal gonorrhoea reflect unsafe sex? Lancet (1991) 3.99
A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. J Infect Dis (1980) 3.96
Prostitute women and public health. BMJ (1988) 3.76
Surveillance of patients attending a diarrhoeal disease hospital in Bangladesh. Br Med J (Clin Res Ed) (1982) 3.75
Attachment of Vibrio cholerae serogroup O1 to zooplankton and phytoplankton of Bangladesh waters. Appl Environ Microbiol (1990) 3.73
Priorities among recommended clinical preventive services. Am J Prev Med (2001) 3.70
Trial of calcium to prevent preeclampsia. N Engl J Med (1997) 3.69
Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum (1981) 3.55
Enterotoxigenic Escherichia coli isolated from food. J Infect Dis (1977) 3.52
Cholera control. Lancet (1994) 3.38
Enterotoxigenic Escherichia coli and Reovirus-like agent in rural Bangladesh. Lancet (1976) 3.38
Laboratory investigation of diarrhea in travelers to Mexico: evaluation of methods for detecting enterotoxigenic Echerichia coli. J Clin Microbiol (1976) 3.34
Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin. J Clin Microbiol (1980) 3.30
Diarrhoea associated with heat-stable enterotoxin-producing strains of Escherichia coli. Lancet (1975) 3.27
Detection of Vibrio cholerae O1 in the aquatic environment by fluorescent-monoclonal antibody and culture methods. Appl Environ Microbiol (1990) 3.21
Optic flow is used to control human walking. Nat Neurosci (2001) 3.12
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
High-molecular-weight plasmid correlates with Escherichia coli enteroinvasiveness. Infect Immun (1982) 2.95
A comparison of three verbal autopsy methods to ascertain levels and causes of maternal deaths in Matlab, Bangladesh. Int J Epidemiol (1998) 2.86
Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med (1978) 2.86
Effect on mortality of community-based maternity-care programme in rural Bangladesh. Lancet (1991) 2.82
Epidemic diarrhea at Crater Lake from enterotoxigenic Escherichia coli. A large waterborne outbreak. Ann Intern Med (1977) 2.80
Candida albicans resistance in AIDS. J Infect (1991) 2.78
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis (1985) 2.78
Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.78
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
Enterotoxigenic Escherichia-coli-associated diarrheal disease in Apache children. N Engl J Med (1975) 2.74
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Microtiter solid-phase radioimmunoassay for detection of Escherichia coli heat-labile enterotoxin. Infect Immun (1977) 2.72
Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci U S A (2003) 2.68
Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development. Lancet (1981) 2.65
Failure of sanitary wells to protect against cholera and other diarrhoeas in Bangladesh. Lancet (1976) 2.64
The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60
El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect (2009) 2.60
The burden of cholera in the slums of Kolkata, India: data from a prospective, community based study. Arch Dis Child (2005) 2.59
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis (1988) 2.57
Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. Int J Epidemiol (1991) 2.56
Improved thin-layer chromatographic method for the separation of major phospholipids and glycolipids from plant lipid extracts and phosphatidyl glycerol and bis(monoacylglyceryl) phosphate from animal lipid extracts. J Chromatogr (1977) 2.55
Cholera in India: an analysis of reports, 1997-2006. Bull World Health Organ (2010) 2.52
HTLV-III: should testing ever be routine? Br Med J (Clin Res Ed) (1986) 2.51
Radiation therapy of early carcinoma of the breast without mastectomy. Cancer (1980) 2.49
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A (1993) 2.48
Studies of cellular immunity in male homosexuals in London. Lancet (1983) 2.41
An educational intervention for altering water-sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. Am J Epidemiol (1987) 2.38
Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA (1998) 2.37
Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA (1999) 2.34
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest (1990) 2.33
Virulence and phenotypic characterization of Yersinia enterocolitica isolated from humans in the United States. J Clin Microbiol (1983) 2.32
Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet (1987) 2.32
The complete set of predicted genes from Saccharomyces cerevisiae in a readily usable form. Genome Res (1997) 2.31
A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med (1984) 2.27
Rape and subsequent seroconversion to HIV. BMJ (1989) 2.26
Barriers to vaccinating preschool children. J Health Care Poor Underserved (1990) 2.26
Twenty-four-hour recall, knowledge-attitude-practice questionnaires, and direct observations of sanitary practices: a comparative study. Bull World Health Organ (1987) 2.24
The relationship between shaved margin and inked margin status in breast excision specimens. Cancer (1997) 2.22
Improved methodology for analyzing local and distant recurrence. J Clin Oncol (1990) 2.21
Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med (2000) 2.20
Tissue-culture assay of antibodies to heat-liable Escherichia coli enterotoxins. N Engl J Med (1974) 2.20
Serum cotinine concentration and self-reported smoking during pregnancy. Am J Epidemiol (1998) 2.15
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Classical Vibrio cholerae biotype displaces EL tor in Bangladesh. Lancet (1983) 2.12
Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys (1979) 2.10
Methods for priority setting among clinical preventive services. Am J Prev Med (2001) 2.05
Decline in maternal mortality in Matlab, Bangladesh: a cautionary tale. Lancet (1998) 2.04
Three-year prospective study of HTLV-III/LAV infection in homosexual men. Lancet (1986) 2.04
Enterotoxigenic Escherichia coli isolated from patients at a hospital in Dacca. J Infect Dis (1977) 2.03